About Scribe Therapeutics
Scribe Therapeutics specializes in genetic medicine, utilizing CRISPR technology to develop solutions for genetic diseases. CRISPR acts like molecular scissors, allowing for precise alterations in DNA sequences to potentially correct genetic defects. The company serves healthcare providers, research institutions, and pharmaceutical companies, operating in a growing market projected to reach $10.1 billion by 2026. Scribe Therapeutics develops and licenses its proprietary CRISPR-based platform, generating revenue through partnerships and technology licensing. Additionally, it is working on advanced delivery methods for in vivo genetic medicine, focusing on precise targeting of specific gene variants to treat genetic disorders. The goal of Scribe Therapeutics is to pioneer advancements in genetic medicine through its innovative CRISPR applications.